Skip to main content
Top
Published in: Investigational New Drugs 3/2020

01-06-2020 | Pancreatic Cancer | PRECLINICAL STUDIES

LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer

Authors: Yong Tang, Guojun Cao, Gang Zhao, Chunyou Wang, Qi Qin

Published in: Investigational New Drugs | Issue 3/2020

Login to get access

Summary

Background It is well-known that long-chain non-coding RNA (LncRNA) plays an important role in the development of tumor. DANCR, which is one crucial part of the lncRNA family, has been shown to be involved in the invasion of various tumors. However, its molecular mechanism in pancreatic cancer remains unknown. Methods qRT-PCR was used to detect the expression of DANCR, miR-135a mRNA in pancreatic cancer tissues or cells. E-cadherin and NLRP3 protein levels were measured by Western Blot. CCK-8, cell scratch, and transwell assays were applied to detect the proliferation and invasion of pancreatic cancer cells. Bioinformatical analysis and luciferase assay were performed to explore the relationship among DANCR, miR-135a and NLRP3. Results In pancreatic cancer, DANCR was up-regulated while miR-135a was down-regulated. The over-expression of DANCR promoted the proliferation and invasion of pancreatic cancer cells. A negative relationship was found between DANCR and miR-135a expression. Moreover, we found that miR-135a reversed the effects of DANCR in the promoting of pancreatic cancer cells, which was achieved by regulating the downstream protein of NLRP3. The correlations among DANCR, miR-135a and NLRP3 were confirmed in animal experiments. Conclusion DANCR promoted proliferation and invasion through the regulating of miR-135a / NLRP3 axis in pancreatic cancer cell. Our results suggest that DANCR may be a potential target for the therapy of pancreatic cancer.
Literature
1.
go back to reference Bray F, Ren JS, Masuyer E, Ferlay J (2013) "Global estimates of cancer prevalence for 27 sites in the adult population in 2008," (in eng). Int J Cancer, Research Support, Non-U.S. Gov't 132(5):1133–1145CrossRef Bray F, Ren JS, Masuyer E, Ferlay J (2013) "Global estimates of cancer prevalence for 27 sites in the adult population in 2008," (in eng). Int J Cancer, Research Support, Non-U.S. Gov't 132(5):1133–1145CrossRef
2.
go back to reference Ilic M, Ilic I (2016) "Epidemiology of pancreatic cancer," (in eng). World J Gastroenterol, Review 22(44):9694–9705CrossRef Ilic M, Ilic I (2016) "Epidemiology of pancreatic cancer," (in eng). World J Gastroenterol, Review 22(44):9694–9705CrossRef
3.
go back to reference Ferlay J et al (2015) "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012," (in eng). Int J Cancer 136(5):E359–E386CrossRef Ferlay J et al (2015) "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012," (in eng). Int J Cancer 136(5):E359–E386CrossRef
4.
go back to reference Kanda M et al (2012) "Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia," (in eng). Gastroenterology, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 142(4):730–733 e9CrossRef Kanda M et al (2012) "Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia," (in eng). Gastroenterology, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 142(4):730–733 e9CrossRef
5.
go back to reference Bertone P et al (2004) "Global identification of human transcribed sequences with genome tiling arrays," (in eng). Science, Research Support, U.S. Gov't, P.H.S 306(5705):2242–2246CrossRef Bertone P et al (2004) "Global identification of human transcribed sequences with genome tiling arrays," (in eng). Science, Research Support, U.S. Gov't, P.H.S 306(5705):2242–2246CrossRef
6.
go back to reference Zhang D, Xiong M, Xu C, Xiang P, Zhong X (2016) "Long noncoding RNAs: an overview," (in eng). Methods Mol Biol, Research Support, Non-US Gov't Review 1402:287–295CrossRef Zhang D, Xiong M, Xu C, Xiang P, Zhong X (2016) "Long noncoding RNAs: an overview," (in eng). Methods Mol Biol, Research Support, Non-US Gov't Review 1402:287–295CrossRef
7.
go back to reference Bhan A, Mandal SS (2015) "LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer," (in eng). Biochim Biophys Acta, Research Support, NIH, Extramural Review 1856(1):151–164PubMedPubMedCentral Bhan A, Mandal SS (2015) "LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer," (in eng). Biochim Biophys Acta, Research Support, NIH, Extramural Review 1856(1):151–164PubMedPubMedCentral
8.
go back to reference Zuo ZK et al (Feb 2017) "TGFbeta1-induced LncRNA UCA1 upregulation promotes gastric Cancer invasion and migration," (in eng). DNA Cell Biol 36(2):159–167CrossRef Zuo ZK et al (Feb 2017) "TGFbeta1-induced LncRNA UCA1 upregulation promotes gastric Cancer invasion and migration," (in eng). DNA Cell Biol 36(2):159–167CrossRef
9.
go back to reference Ma X et al (Dec 2016) "DANCR acts as a diagnostic biomarker and promotes tumor growth and metastasis in hepatocellular carcinoma," (in eng). Anticancer Res 36(12):6389–6398CrossRef Ma X et al (Dec 2016) "DANCR acts as a diagnostic biomarker and promotes tumor growth and metastasis in hepatocellular carcinoma," (in eng). Anticancer Res 36(12):6389–6398CrossRef
10.
go back to reference Jia J et al (2016) Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3, (in eng). Oncotarget 7(25):37868–37881CrossRef Jia J et al (2016) Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3, (in eng). Oncotarget 7(25):37868–37881CrossRef
11.
go back to reference Yang ZY et al (2017) "LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression," (in eng). Cancer Biomark 18(1):95–104CrossRef Yang ZY et al (2017) "LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression," (in eng). Cancer Biomark 18(1):95–104CrossRef
12.
go back to reference Liu Y, Zhang M, Liang L, Li J, Chen YX (2015) Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer," (in eng. Int J Clin Exp Pathol 8(9):11480–11484PubMedPubMedCentral Liu Y, Zhang M, Liang L, Li J, Chen YX (2015) Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer," (in eng. Int J Clin Exp Pathol 8(9):11480–11484PubMedPubMedCentral
13.
go back to reference Jiang N et al (2017) "lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition," (in eng). Cancer Lett, Research Support, Non-US Gov't 405:46–55CrossRef Jiang N et al (2017) "lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition," (in eng). Cancer Lett, Research Support, Non-US Gov't 405:46–55CrossRef
14.
go back to reference Li J, Zhou L (2018) "Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/beta-catenin signaling," (in eng). Biomed Pharmacother 102:602–607CrossRef Li J, Zhou L (2018) "Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/beta-catenin signaling," (in eng). Biomed Pharmacother 102:602–607CrossRef
15.
go back to reference Voutsadakis IA (2016) "Epithelial-mesenchymal transition (EMT) and regulation of EMT factors by steroid nuclear receptors in breast Cancer: a review and in silico investigation," (in eng). J Clin Med, Review 5(1) Voutsadakis IA (2016) "Epithelial-mesenchymal transition (EMT) and regulation of EMT factors by steroid nuclear receptors in breast Cancer: a review and in silico investigation," (in eng). J Clin Med, Review 5(1)
16.
go back to reference Voutsadakis IA (2012) "Ubiquitination and the ubiquitin-proteasome system as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer," (in eng). Tumour Biol, Review 33(4):897–910CrossRef Voutsadakis IA (2012) "Ubiquitination and the ubiquitin-proteasome system as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer," (in eng). Tumour Biol, Review 33(4):897–910CrossRef
17.
go back to reference Pan L et al (2018) Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells," (in eng. Oncotarget 9(2):1915–1930CrossRef Pan L et al (2018) Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells," (in eng. Oncotarget 9(2):1915–1930CrossRef
18.
go back to reference Lu QC, Rui ZH, Guo ZL, Xie W, Shan S, Ren T (2018) "LncRNA-DANCR contributes to lung adenocarcinoma progression by sponging miR-496 to modulate mTOR expression," (in eng). J Cell Mol Med 22(3):1527–1537CrossRef Lu QC, Rui ZH, Guo ZL, Xie W, Shan S, Ren T (2018) "LncRNA-DANCR contributes to lung adenocarcinoma progression by sponging miR-496 to modulate mTOR expression," (in eng). J Cell Mol Med 22(3):1527–1537CrossRef
19.
go back to reference Pan HW, Li SC, Tsai KW (2013) "MicroRNA dysregulation in gastric cancer," (in eng). Curr Pharm Des, Research Support, Non-US Gov't Review 19(7):1273–1284PubMed Pan HW, Li SC, Tsai KW (2013) "MicroRNA dysregulation in gastric cancer," (in eng). Curr Pharm Des, Research Support, Non-US Gov't Review 19(7):1273–1284PubMed
Metadata
Title
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer
Authors
Yong Tang
Guojun Cao
Gang Zhao
Chunyou Wang
Qi Qin
Publication date
01-06-2020
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-019-00798-0

Other articles of this Issue 3/2020

Investigational New Drugs 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine